Metoprolol Tartrate Amlodipine Tablet
Description
ROOTOPINE-M
Metoprolol Tartrate and Amlodipine Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Metoprolol Tartrate IP — 25 mg / 50 mg
Amlodipine Besylate IP equivalent to Amlodipine — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
ROOTOPINE-M is a well-balanced antihypertensive combination of Metoprolol Tartrate and Amlodipine, formulated for the effective management of hypertension, angina pectoris, and cardiovascular risk reduction. This combination provides dual blood pressure control by combining the cardioselective beta-blocking action of Metoprolol with the potent vasodilatory effect of Amlodipine, resulting in superior blood pressure reduction and improved cardiovascular protection.
Metoprolol Tartrate is a selective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand. Amlodipine is a long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reduces peripheral vascular resistance, and improves coronary blood flow.
ROOTOPINE-M is particularly beneficial in patients with hypertension associated with tachycardia, angina, coronary artery disease, diabetes, metabolic syndrome, and high cardiovascular risk. The combination helps achieve better blood pressure control while reducing the workload on the heart and improving exercise tolerance in patients with angina.
Technical Knowledge of Metoprolol Tartrate and Amlodipine
Metoprolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin release from the kidneys. This leads to a reduction in cardiac output and blood pressure.
Amlodipine inhibits L-type calcium channels in vascular smooth muscle, causing peripheral arterial vasodilation, reduced systemic vascular resistance, and decreased afterload. It also improves coronary artery perfusion and helps prevent coronary vasospasm.
The combination of Metoprolol and Amlodipine provides complementary antihypertensive mechanisms, improving blood pressure control while minimizing reflex tachycardia and enhancing cardiovascular protection.
Mechanism of Action
Metoprolol reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand.
Amlodipine relaxes vascular smooth muscle, reduces peripheral vascular resistance, lowers afterload, improves coronary blood flow, and provides sustained blood pressure control.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides dual antihypertensive action
Reduces heart rate and myocardial workload
Improves coronary blood flow
Helps control angina symptoms
Reduces cardiovascular risk
Improves exercise tolerance
Provides sustained 24-hour blood pressure control
Suitable for long-term hypertension management under medical supervision
Clinical Applications
ROOTOPINE-M is commonly prescribed for essential hypertension, hypertension with tachycardia, chronic stable angina, coronary artery disease, hypertension with diabetes, hypertension with metabolic syndrome, cardiovascular risk reduction, and patients requiring combination antihypertensive therapy.
Facts About Metoprolol Tartrate and Amlodipine
Metoprolol is one of the most extensively used cardioselective beta-blockers for hypertension and ischemic heart disease. Amlodipine is a long-acting calcium channel blocker with excellent antihypertensive efficacy and once-daily blood pressure control. The combination is widely used for patients requiring both heart rate control and effective peripheral vasodilation.
Key Facts
Dual antihypertensive combination therapy
Beta-blocker and calcium channel blocker combination
Effective in hypertension and angina
Reduces cardiac workload and vascular resistance
Supports long-term cardiovascular protection
Evidence-based combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ROOTOPINE-M is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose ROOTOPINE-M for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Tartrate and Amlodipine Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
ROOTOPINE-M from DIABGLYM combines effective blood pressure control, heart rate reduction, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based antihypertensive combination.
